New drug combo shows promise for rare salivary gland cancer
NCT ID NCT07464366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not yet complete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACINIC CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a targeted drug shrink rare salivary gland tumors?
- Can sequencing immunotherapy before chemo boost stomach cancer outcomes?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- New drug cocktail targets genetic weakness in rare cancer
- Drug duo takes on rare head and neck tumors